Brought to you by 
Gynesonics brings in $75mm in late-stage funding
21 Feb 2019
Executive Summary
Gynesonics Inc. (minimally invasive devices for women's health) closed a $75mm late-stage equity round led by Bain Capital Life Sciences (added a board member), which was joined by returning investors, including Abingworth, Advanced Technology Ventures, Endeavour Vision, HealthCrest, InterWest Partners, HBM Partners, Correlation Ventures, and Hercules Technology Growth Capital. The company will use the funds to support launch and commercialization activities for its Sonata (sonography-guided intrauterine imaging and transcervical radiofrequency ablation system for symptomatic uterine fibroids), which is both CE Marked (June 2014) and 510(k) cleared (August 2018). Gynesonics will also put some of the proceeds toward further development of the Sonata platform and clinical research initiatives for reimbursement and market development purposes.
Deal Industry
- Medical Devices
-
Medical Devices
- Radiofrequency Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Diagnostic Imaging Equipment & Supplies
- Ultrasound
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gynesonics brings in $75mm in late-stage funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice